LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients

被引：6

作者：

Altinbas, Akif ^{[1
,2
]}

Holmes, Jacinta A. ^{[1
,2
]}

Salloum, Shadi ^{[1
,2
]}

Lidofsky, Anna ^{[1
,2
]}

Alatrakchi, Nadia ^{[1
,2
]}

Somsouk, Ma ^{[3
]}

Hunt, Peter ^{[3
]}

Deeks, Steven ^{[3
]}

Chew, Kara W. ^{[4
]}

Lauer, Georg ^{[1
,2
]}

Kruger, Annie ^{[1
,2
]}

Lin, Wenyu ^{[1
,2
]}

Chung, Raymond T. ^{[1
,2
]}

机构：

[1] Harvard Med Sch, Dept Med, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA

[4] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

BIOMARKERS IN MEDICINE | 2022年 / 16卷 / 11期

基金：

美国国家卫生研究院;

关键词：

antiretroviral therapy; hepatitis C virus infection; HIV infection; liver fibrosis; LOXL-2; peginterferon and ribavirin therapy; TNC-C; CHRONIC HEPATITIS; TENASCIN-C; FIBROSIS; EXPRESSION; DISEASE;

D O I：

10.2217/bmm-2021-0596

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Lysil oxidase like enzyme-2 (LOXL-2) and TNC-C play important roles in organ fibrosis. We assessed circulating LOXL-2 and TNC-C levels and their relationship to fibrosis severity in HIV- and/or HCV-infected individuals. Methods: Healthy controls (n = 22), HIV mono- (n = 15), HCV mono- (n = 52) and HCV/HIV- co-infected (n = 92) subjects were included. Results: LOXL-2 and TNC-C levels were significantly higher in HCV mono- and HCV/HIV-co-infected individuals with F0 compared to healthy controls. In addition, in HCV/HIV-co-infected individuals, LOXL-2 levels were higher in intermediate fibrosis compared to no/mild fibrosis. Conclusion: In HCV/HIV-co-infected study participants, both LOXL-2 and TNC-C were significantly higher in intermediate fibrosis compared to no/mild fibrosis, but did not further increase with advanced fibrosis. Furthermore, both markers were elevated among HCV/HIV-positive individuals with mild/no fibrosis.

引用

页码：839 / 846

页数：8

共 30 条

[1]

Afdhal NH., 2015, HEPATOLOGY 62 S1, p582A

[2] A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product? [J].

Altinbas, Akif .

MEDICAL HYPOTHESES, 2017, 108 :159-160

[3] Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results [J].

Basar, Omer ;

Yimaz, Baris ;

Ekiz, Fuat ;

Ginis, Zeynep ;

Altinbas, Akif ;

Aktas, Bora ;

Tuna, Yasar ;

Coban, Sahin ;

Delibas, Namik ;

Yuksel, Osman .

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (02) :152-158

[4]

Baser Onur, 2015, Value Health Reg Issues, V7, P42, DOI [10.1016/j.vhri.2015.08.004, 10.1016/j.vhri.2015.08.004]

[5] Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study [J].

Benbow, Jennifer H. ;

Elam, April D. ;

Bossi, Krista L. ;

Massengill, Danae L. ;

Brandon-Warner, Elizabeth ;

Anderson, William E. ;

Culberson, Catherine R. ;

Russo, Mark W. ;

deLemos, Andrew S. ;

Schrum, Laura W. .

DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) :653-664

[6] Apoptosis: The nexus of liver injury and fibrosis [J].

Canbay, A ;

Friedman, S ;

Gores, GJ .

HEPATOLOGY, 2004, 39 (02) :273-278

[7] HCV and HIV co-infection: mechanisms and management [J].

Chen, Jennifer Y. ;

Feeney, Eoin R. ;

Chung, Raymond T. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2014, 11 (06) :362-371

[8] Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis [J].

Chen, Wei ;

Yang, Aiting ;

Jia, Jidong ;

Popov, Yury, V ;

Schuppan, Detlef ;

You, Hong .

HEPATOLOGY, 2020, 72 (02) :729-741

[9] Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].

Chung, RT ;

Andersen, J ;

Volberding, P ;

Robbins, GK ;

Liu, T ;

Sherman, KE ;

Peters, MG ;

Koziel, MJ ;

Bhan, AK ;

Alston, B ;

Colquhoun, D ;

Nevin, T ;

Harb, G ;

van der Horst, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459

[10] Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice [J].

El-Karef, A. ;

Yoshida, T. ;

Gabazza, E. C. ;

Nishioka, T. ;

Inada, H. ;

Sakakura, T. ;

Imanaka-Yoshida, K. .

JOURNAL OF PATHOLOGY, 2007, 211 (01) :86-94

← 1 2 3 →